scholarly journals Circulating 25-Hydroxyvitamin D Levels in Fully Breastfed Infants on Oral Vitamin D Supplementation

2010 ◽  
Vol 2010 ◽  
pp. 1-5 ◽  
Author(s):  
Carol L. Wagner ◽  
Cindy Howard ◽  
Thomas C. Hulsey ◽  
Ruth A. Lawrence ◽  
Sarah N. Taylor ◽  
...  
Keyword(s):  
Vitamin D ◽  
Vitamin D Supplementation ◽  
Vitamin Supplementation ◽  
Oral Vitamin ◽  
Oil Emulsion ◽  
Hydroxyvitamin D ◽  
Breastfed Infants ◽  
25 Hydroxyvitamin D ◽  
The Mean ◽  
Nutritional Vitamin

Objective. To examine the effectiveness of oral vitamin (400 IU) supplementation on the nutritional vitamin D status of breastfeeding infants.Design. As part of a larger ongoing vitamin D RCT trial of lactating women, infants of mothers assigned to control received 1 drop of 400 IU vitamin /day starting at one month of age. Infant 25(OH)D levels (mean S.D.) were measured by RIA at visits 1, 4, and 7.Results. The infant mean S.D. 25(OH)D at baseline was 16.0 9.3 ng/mL (range 1.0–40.8; ); 24 (72.7%) had baseline levels <20 ng/mL (consistent with deficiency). The mean levels increased to 43.6 14.1 (range 18.2–69.7) at 4 months and remained relatively unchanged at month 7: 42.5 12.1 ng/mL (range 18.9–67.2). The change in values between 1 and 4 months and 1 and 7 months was statistically significant , and despite a decrease in dose per kilogram, values were not significantly different between months 4 and 7 .Conclusions. Oral vitamin supplementation as an oil emulsion was associated with significant and sustained increases in 25(OH)D from baseline in fully breastfeeding infants through 7 months.

Vitamin D Level Stability in Dystrophinopathy Patients on Vitamin D Supplementation

2021 ◽  
pp. 1-7
Author(s):  
Naomi Vather-Wu ◽  
Matthew D. Krasowski ◽  
Katherine D. Mathews ◽  
Amal Shibli-Rahhal
Keyword(s):  
Vitamin D ◽  
Retrospective Cohort ◽  
Vitamin D Supplementation ◽  
Hydroxyvitamin D ◽  
Frequent Monitoring ◽  
25 Hydroxyvitamin D ◽  
The Mean ◽  
Stable Maintenance ◽  
Mean Time

Background: Expert guidelines recommend annual monitoring of 25-hydroxyvitamin D (25-OHD) and maintaining 25-OHD ≥30 ng/ml in patients with dystrophinopathies. Objective: We hypothesized that 25-OHD remains stable and requires less frequent monitoring in patients taking stable maintenance doses of vitamin D. Methods: We performed a retrospective cohort study, using the electronic health record to identify 26 patients with dystrophinopathies with a baseline 25-OHD ≥30 ng/mL and at least one additional 25-OHD measurement. These patients had received a stable dose of vitamin D for ≥3 months prior to their baseline 25-OHD measurement and throughout follow-up. The main outcome measured was the mean duration time the subjects spent with a 25-OHD ≥30 ng/mL. Results: Only 19% of patients dropped their 25-OHD to <  30 ng/ml, with a mean time to drop of 33 months and a median nadir 25-OHD of 28 ng/mL. Conclusions: These results suggest that measurement of 25-OHD every 2–2.5 years may be sufficient in patients with a baseline 25-OHD ≥30 ng/mL and who are on a stable maintenance dose of vitamin D. Other patients may require more frequent assessments.

scholarly journals Oral vitamin D supplementation has a lower bioavailability and reduces hypersecretion of parathyroid hormone and insulin resistance in obese Chinese males

2014 ◽  
Vol 18 (12) ◽  
pp. 2211-2219 ◽  
Author(s):  
Ji-Chang Zhou ◽  
Yu-Mei Zhu ◽  
Zheng Chen ◽  
Jun-Luan Mo ◽  
Feng-Zhu Xie ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Vitamin D ◽  
Parathyroid Hormone ◽  
Vitamin D Supplementation ◽  
Normal Weight ◽  
Vitamin D Status ◽  
Intervention Trial ◽  
Oral Vitamin ◽  
Hydroxyvitamin D ◽  
25 Hydroxyvitamin D

AbstractObjectiveTo examine the vitamin D status, SNP of the vitamin D receptor gene (VDR) and the effects of vitamin D supplementation on parathyroid hormone and insulin secretion in adult males with obesity or normal weight in a subtropical Chinese city.DesignAn intervention trial.SettingShenzhen City, Guangdong Province, China.SubjectsFrom a cross-sectional survey conducted from June to July, eighty-two normal-weight and ninety-nine obese males (18–69 years) were screened to analyse their vitamin D status and for five SNP of VDR. From these individuals, in the same season of a different year, obese and normal-weight male volunteers (twenty-one per group) were included for an intervention trial with oral vitamin D supplementation at 1250 µg/week for 8 weeks.ResultsFor the survey, there was no significant difference (P>0·05) in baseline circulating 25-hydroxyvitamin D concentrations or in the percentages of participants in different categories of vitamin D status between the two groups. The VDR SNP, rs3782905, was significantly associated with obesity (P=0·043), but none of the examined SNP were correlated with serum 25-hydroxyvitamin D when adjusted for age, BMI and study group. After vitamin D supplementation, serum 25-hydroxyvitamin D concentration, hypersecretions of parathyroid hormone and insulin, and insulin resistance in the obese were changed beneficially (P<0·05); however, the increase in serum 25-hydroxyvitamin D was less than that of the normal-weight men.ConclusionsFor obese and normal-weight men of subtropical China, the summer baseline vitamin D status was similar. However, oral vitamin D supplementation revealed a decreased bioavailability of vitamin D in obese men and ameliorated their hypersecretion of parathyroid hormone and insulin resistance.

scholarly journals Fall in Vitamin D Levels during Hospitalization in Children

2014 ◽  
Vol 2014 ◽  
pp. 1-6 ◽  
Author(s):  
Devi Dayal ◽  
Suresh Kumar ◽  
Naresh Sachdeva ◽  
Rakesh Kumar ◽  
Meenu Singh ◽  
...  
Keyword(s):  
Vitamin D ◽  
Hospital Stay ◽  
Vitamin D Supplementation ◽  
Healthcare Associated Infection ◽  
Hydroxyvitamin D ◽  
Vitamin D Levels ◽  
25 Hydroxyvitamin D ◽  
The Mean ◽  
The Difference ◽  
Healthcare Associated

Plasma levels of 25-hydroxyvitamin D [25(OH)D] were measured by competitive Electrochemiluminescence Immunoassay (ECLIA) in 92 children (67 boys, 25 girls) aged 3 months to 12 years at admission to hospital (timepoint 1, T1) and at discharge (timepoint 2, T2). There was a significant fall in the mean 25(OH)D from T1 (71.87 ± 27.25 nmol/L) to T2 (49.03 ± 22.25 nmol/L) (mean change = 22.84 nmol/L,Pvalue = 0.0004). Proportion of patients having VDD (levels <50 nmol/L) at admission (25%, 23/92) increased significantly at the time of discharge (51.09%, 47/92) (P=0.0004). There was a trend towards longer duration of hospital stay, requirement of ventilation and inotropes, development of healthcare-associated infection, and mortality in vitamin D deficient as compared to nondeficient patients though the difference was statistically insignificant. In conclusion, vitamin D levels fall significantly and should be monitored during hospital stay in children. Large clinical studies are needed to prospectively evaluate the effect of vitamin D supplementation in vitamin D deficient hospitalized children on various disease outcome parameters.

scholarly journals The efficacy of vitamin D3 supplementation in increasing 25-hydroxyvitamin D levels in childhood vitiligo patients receiving 308-nm-excimer light phototherapy

2019 ◽  
Author(s):  
Reiva Farah Dwiyana ◽  
Pramita K.C. Nugrahaini ◽  
D.P. Larasati ◽  
Inne Arline Diana ◽  
Reti Hindritiani ◽  
...  
Keyword(s):  
Vitamin D ◽  
Combination Therapy ◽  
Vitamin D3 ◽  
Vitamin D Supplementation ◽  
Oral Vitamin ◽  
Once Daily ◽  
Hydroxyvitamin D ◽  
Group I ◽  
Vitamin D3 Supplementation ◽  
25 Hydroxyvitamin D

Vitamin D deficiency is a condition often found in various autoimmune diseases, including vitiligo. There were clinical improvements in autoimmune patients who had been given oral vitamin D supplementation, as well as vitiligo patients. This study aimed to analyze the comparison effect of a combination therapy of 308-nmexcimer light phototherapy and vitamin D3 supplementation toward 308-nm-excimer light phototherapy alone to increase of serum 25-(OH)D levels in childhood vitiligo patients. Subjects consisted of 16 childhood vitiligo patients that divided into two groups; group I was given a combination of 308-nm-excimer light phototherapy and 5000 IU of vitamin D3 supplement once daily, while group II was given monotherapy of excimer light. There were highly significant increase of 25-(OH)D serum in both groups which were 324.00±119.066% and 29.84±36.106%, respectively. The very significant result was seen in a comparison of average increased of serum 25-(OH)D levels between both groups. The study concluded that combination of 308-nm-excimer light phototherapy and vitamin D3 supplementation gave a better effect than phototherapy only to increase of serum 25- (OH)D levels in childhood vitiligo patients.

Bone Density and Cortical Thickness in Nutritional Vitamin D Deficiency: Effect of Secondary Hyperparathyroidism

1988 ◽  
Vol 25 (3) ◽  
pp. 271-274 ◽  
Author(s):  
V Fonseca ◽  
J E Agnew ◽  
D Nag ◽  
P Dandona
Keyword(s):  
Vitamin D ◽  
Secondary Hyperparathyroidism ◽  
Cortical Thickness ◽  
Hypovitaminosis D ◽  
Vitamin D Supplementation ◽  
Plasma Calcium ◽  
Hydroxyvitamin D ◽  
Asymptomatic Patients ◽  
25 Hydroxyvitamin D ◽  
Nutritional Vitamin

Measurements of bone mineral index, mean metacarpal cortical thickness, plasma calcium, alkaline phosphatase and serum 25-hydroxyvitamin D and parathyroid hormone concentrations were carried out in 39 Asian vegetarian patients with hypovitaminosis D. It was concluded that PTH is probably the major determinant of osteopenia in patients with osteomalacia and secondary hyperparathyroidism; and that the presence of secondary hyperparathyroidism in association with hypovitaminosis D should be an absolute indication for vitamin D supplementation even in asymptomatic patients.

scholarly journals A phase I study of oral vitamin D3 supplementation in boys with X-linked adrenoleukodystrophy

2022 ◽  
Author(s):  
Keith Van Haren ◽  
Kristen Cunanan ◽  
Avni Awani ◽  
Meng Gu ◽  
Dalia Pena ◽  
...  
Keyword(s):  
Vitamin D ◽  
Phase I Study ◽  
Vitamin D Supplementation ◽  
Brain Lesions ◽  
Fixed Dose ◽  
Dosing Regimen ◽  
Oral Vitamin ◽  
Hydroxyvitamin D ◽  
Vitamin D Levels ◽  
25 Hydroxyvitamin D

Objective: Vitamin D status has been linked to risk of inflammatory brain lesions. We sought to assess the safety and pharmacokinetics of oral vitamin D dosing regimens in boys with X-linked adrenoleukodystrophy (ALD). Methods: In this open-label, multi-center, phase I study, we enrolled 21 ALD males without brain lesions, aged 1.5 to 25 years to oral vitamin D supplementation for 12 months. Our primary outcome was attainment of plasma 25-hydroxyvitamin D levels in target range (40-80ng/ml) at 6 and 12 months. Secondary outcomes included safety and glutathione levels in brain and blood. Participants were initially assigned to a fixed dosing regimen starting at 2,000 IU daily, regardless of weight. Following a mid-study safety assessment, we modified the dosing regimen so all subsequent participants were assigned to a weight-stratified dosing regimen starting as low as 1,000 IU daily. Results: Between October 2016 and June 2019, we recruited 21 participants (n=12 fixed dose; n=9 weight-stratified) with a median age and weight of 6.7 years and 20 kilograms. Most participants achieved target plasma vitamin D levels at 6 and 12 months regardless of dosing regimen. In the fixed dose regimen, 6 of 12 participants had asymptomatic elevation in urine calcium:creatinine or plasma 25-hydroxyvitamin D; no laboratory deviations occurred with the weight-stratified regimen. Glutathione levels increased between baseline and 12 months in the brain but not in the blood. Conclusions: Our weight-stratified vitamin D dosing regimen was well-tolerated and achieved target 25-hydroxyvitamin D levels in most participants. Brain glutathione levels increased over the 12-month trial period. Classification of Evidence: This study provides Class II evidence that a weight-stratified dosing regimen of vitamin D supplementation is safe, well-tolerated, and effective at achieving moderately high vitamin D levels in boys with ALD.

Impact of oral vitamin D supplementation on serum 25-hydroxyvitamin D levels in oncology.

2010 ◽  
Vol 28 (15_suppl) ◽  
pp. e19542-e19542
Author(s):  
C. A. Lammersfeld ◽  
P. G. Vashi ◽  
K. Trukova ◽  
D. P. Braun ◽  
D. Gupta
Keyword(s):  
Vitamin D ◽  
Vitamin D Supplementation ◽  
Oral Vitamin ◽  
Hydroxyvitamin D ◽  
25 Hydroxyvitamin D

scholarly journals Impact of oral vitamin D supplementation on serum 25-hydroxyvitamin D levels in oncology

2010 ◽  
Vol 9 (1) ◽  
Author(s):  
Pankaj G Vashi ◽  
Kristen Trukova ◽  
Carolyn A Lammersfeld ◽  
Donald P Braun ◽  
Digant Gupta
Keyword(s):  
Vitamin D ◽  
Vitamin D Supplementation ◽  
Oral Vitamin ◽  
Hydroxyvitamin D ◽  
25 Hydroxyvitamin D

scholarly journals Discrimination in the metabolism of orally dosed ergocalciferol and cholecalciferol by the pig, rat and chick

1982 ◽  
Vol 204 (1) ◽  
pp. 185-189 ◽  
Author(s):  
R L Horst ◽  
J L Napoli ◽  
E T Littledike
Keyword(s):  
Vitamin D ◽  
World Monkey ◽  
Vitamin Supplementation ◽  
Dietary Vitamin ◽  
Species Discrimination ◽  
Vitamin D Metabolism ◽  
Hydroxyvitamin D ◽  
25 Hydroxyvitamin D ◽  
The Mean ◽  
Oral Doses

Vitamin D-deficient pigs, rats and chicks were repleted with four daily oral doses of crystalline ergocalciferol (vitamin D2) and cholecalciferol (vitamin D3) containing equal concentrations of each. At 24 h after the last dose, the plasma of each species was analysed for vitamin D and 25-hydroxyvitamin D by standard methods. The mean (+/- S.D.) ratios of plasma cholecalciferol to ergocalciferol concentration were 1.5 +/- 0.1 (pig). 1.7 +/- 0.1 (rat) and 6.3 +/- 1.2 (chick). The mean ratios of plasma 25-hydroxycholecalciferol to 25-hydroxyergocalciferol concentration were 4.0 +/- 0.1 (pig), 0.4 +/- 0.02 (rat) and 10.7 +/- 3.4 (chick). The mean plasma cholecalciferol/ergocalciferol ratios for the 24,25-dihydroxy-, 25,26-dihydroxy- and 1,25-dihydroxy-derivatives in the pig were 2.6 +/- 0.6, 5.8 +/- 1.3 and 5.8 +/- 0.8 respectively. This is the first evidence that mammals other than the New World monkey, like birds, discriminate between ergocalciferol and cholecalciferol. These data, therefore, suggest that species discrimination between the different forms of vitamin D is probably a general phenomenon in mammals. Moreover, this is the first indication of a species (rat) that discriminates against a cholecalciferol metabolite in favour of an ergocalciferol metabolite. Species discrimination against particular forms of vitamin D may be important to the choice of experimental animal models for studying the regulation of vitamin D metabolism and may also be an important consideration in dietary vitamin supplementation.

Sign in / Sign up

Export Citation Format

Share Document